Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma [Phase 3]
Phase 3 trial evaluating ibrutinib before and after stem cell transplantation in relapsed or refractory diffuse large B-cell lymphoma (activ…
-
CLINICAL_TRIALS trial_result · 2025-09-29Clinical Trial Update: Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma [Phase 2]
A Phase 2 clinical trial update notes Polatuzumab Vedotin in combination chemotherapy for previously untreated diffuse large B-cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2025-09-25Clinical Trial Update: LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) [Phase 1, Phase 2]
Phase 1/2 LOC-R01 study evaluates lenalidomide and ibrutinib in combination with Rituximab-Methotrexate-Procarbazine-Vincristine (R-MPV) for…
-
CLINICAL_TRIALS trial_result · 2025-09-18Clinical Trial Update: Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.
Completed clinical trial update reporting molecular characterization and outcomes in aggressive B-cell lymphomas, including Diffuse Large B-…
-
CLINICAL_TRIALS trial_result · 2025-09-15Clinical Trial Update: Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab [Phase 1, Phase 2]
The Phase 1/2 trial evaluates Ociperlimab (BGB-A1217) in combination with tislelizumab or rituximab for relapsed or refractory diffuse large…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-09-10Clinical Trial Update: BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) [Phase 1]
Phase I clinical trial update for BR101801 in adults with advanced hematologic malignancies; the study has completed.
-
CLINICAL_TRIALS trial_result · 2025-09-05Clinical Trial Update: Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating maplirpacept in combination with tafasitamab and lenalidomide for relapsed or refractory diffuse large B-cell lym…
-
CLINICAL_TRIALS trial_result · 2025-09-03Clinical Trial Update: A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma [Phase 2]
Phase 2 study evaluating two Rituximab-containing chemotherapy regimens with a PET-driven strategy in lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2025-08-28Clinical Trial Update: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies [Phase 1]
The Phase 1 study evaluating AB308 in combination with AB122 in participants with advanced malignancies has been completed.
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers [Phase 1]
This is a Phase 1 clinical trial update for a CAR T cell therapy (19(T2)28z1xx) in various B-cell cancers. The study is sponsored by Memoria…
-
CLINICAL_TRIALS trial_result · 2025-08-21Clinical Trial Update: Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]
This clinical trial update covers Roche's Phase 1/2 study of mosunetuzumab as consolidation after first-line immunochemotherapy and as monot…
-
CLINICAL_TRIALS trial_result · 2025-08-14Clinical Trial Update: Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 study evaluating pirtobrutinib in combination with rituximab, gemcitabine, oxaliplatin, with or without polatuzumab vedotin in coval…
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies [Phase 1]
This update reports a Phase 1 trial of MAK683 in adults with advanced malignancies, including diffuse large B-cell lymphoma, focusing on saf…
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies [Phase 1]
Acepodia Biotech's Phase 1 trial of ACE1831 in adults with relapsed/refractory CD20-expressing B-cell malignancies is currently recruiting a…
-
CLINICAL_TRIALS trial_result · 2025-08-08Clinical Trial Update: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma [Phase 2]
This clinical trial update notes the termination of a Phase 2 study evaluating copanlisib in combination with rituximab-bendamustine for rel…
-
CLINICAL_TRIALS trial_result · 2025-08-07Clinical Trial Update: Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells [Phase 2]
This clinical trial update reports long-term follow-up data from patients treated with Autolus' autologous CAR T cell therapy in multiple my…
-
CLINICAL_TRIALS trial_result · 2025-08-05Clinical Trial Update: A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A completed study evaluating tisagenlecleucel versus standard of care in German adults with relapsed or refractory Diffuse large B-cell lymp…
-
CLINICAL_TRIALS trial_result · 2025-08-03Clinical Trial Update: Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies [Phase 1]
Phase 1 clinical trial update on genetically engineered CAR T cells (EGFRt/19-28z/IL-12) for relapsed or refractory CD19+ hematologic malign…
-
CLINICAL_TRIALS trial_result · 2025-08-01Clinical Trial Update: A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) [Phase 2]
Phase 2 trial comparing BeEAM and BEAM high-dose chemotherapy regimens before autologous stem cell transplantation in lymphoma patients; the…
-
CLINICAL_TRIALS trial_result · 2025-07-28Clinical Trial Update: Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients [Phase 1, Phase 2]
This clinical trial update reports safety and pharmacokinetic data for a modified tafasitamab intravenous dosing regimen in combination with…
-
CLINICAL_TRIALS trial_result · 2025-07-22Clinical Trial Update: FERtility After Therapy With Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow-up
A completed follow-up update on fertility outcomes after intensive lymphoma therapy in young women enrolled in LNH-03 and LNH-07 trials for …
-
CLINICAL_TRIALS trial_result · 2025-07-17Clinical Trial Update: A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2, Phase 3]
A Phase 2/Phase 3 trial compared tafasitamab plus bendamustine to rituximab plus bendamustine in adults with relapsed or refractory diffuse …
-
CLINICAL_TRIALS trial_result · 2025-07-16Clinical Trial Update: Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma
A completed follow-up study evaluating a CD19 CAR-T cell therapy engineered to express IL7 and CCL19 for relapsed or refractory B-cell lymph…
-
CLINICAL_TRIALS trial_result · 2025-07-14Clinical Trial Update: Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 study of AUTO3, a CD19/CD22 CAR T-cell therapy, for relapsed/refractory diffuse large B-cell lymphoma; the trial has terminated wi…
-
CLINICAL_TRIALS trial_result · 2025-07-08Clinical Trial Update: New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement [Phase 2]
Phase 2 trial results evaluating a chemoimmunotherapy combination for systemic diffuse large B-cell lymphoma with CNS involvement. The study…